In Indian pharmaceutical space, drug companies are struggling with eroding margins on generic products and yet, are unable to invest into new drug (NCE/NBE) research due to enormous risk associated with it. In this scenario, the innovative business model of 'Drug Repositioning' pursued by NovaLead Pharma Pvt. Ltd. stands out. This model has potential for NCE-like returns, with much reduced costs & risks.
NovaLead has indigenously developed computational technology for efficient and assured Drug Repositioning. Its first repositioned drug candidate Galnobax targets diabetic foot ulcer (DFU) which is a global unmet need. Untreated DFU often lead to loss of limb and life. Galnobax is presently in Phase 3 clinical development, just a step away from drug approval. If approved, it will be the first small molecule treatment for DFU. Given the limitations of current therapies for DFU, Galnobax brings hope to over 60 million patients globally. In addition to Galnobax, NovaLead has a strong pipeline of repositioned drug candidates at various stages of development addressing diverse therapeutic areas.
On the business side, NovaLead has created an operations model where it retains discovery research in-house. The whole of the subsequent laboratory / development work is entirely outsourced. This allows NovaLead to stay nimble in strategy and efficient in finances. This approach also enables NovaLead to access the best scientific talent around the globe in specific disease areas to support its own research.